New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and patient-important outcomes.

Allowing such medications as options could lead to significant savings from improved health, writes Kelley Koch.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...